- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00814476
The Effects of Regular Home Use Vs Diabetic Team- Supported Use of the Medtronic CareLink Therapy Management System. (CareLink)
The Efficacy, Short and Long Term Effects of Regular Home Use Vs Diabetic Team - Supported Use of the Medtronic CareLink Therapy Management System in Patients With Diabetes
Study Overview
Status
Conditions
Detailed Description
A randomized, two arms, controlled, open study in order to compare the efficacy, short and long term effects of regular home-use Vs diabetic team- supported use of the Medtronic CareLink therapy management system in patients with diabetes.
Primary objective:
To assess the efficacy, short term (4 months) and long term (8 months) effects of using the Medtronic CareLink® Therapy Management System for Diabetes on the following parameters:
- Metabolic control as expressed by HbA1c.
- Hypoglycemic events- number and severity of episodes.
- DKA and ketosis events- number and severity of episodes.
- Patient's satisfaction and quality of life measured by treatment satisfaction and quality of life questionnaires.
- 7 points glucose profile.
Secondary objective:
To compare the efficacy of 4 months treatment using the CareLink® Therapy Management System, accompanied with intensive contact (at least once a month) initiated by diabetic team via the internet/electronic mail Vs home use treatment - without monthly contact initiated by the diabetic team
Study design:
The study will be comprised of two consecutive segments. At the first segment that will last during the first 4 months of the study, patients will be randomized to the CareLink treated group or non CareLink treated group. At this segment of the study the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. At the second segment of the study, during the following 4 months, both groups will use the CareLink system, home-use, without support initiated by the diabetic team.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Petach-Tikva, Israel
- Schnider children medical center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 1 diabetes diagnosed at least 6 months prior to study entry
- Current treatment with Medtronic 722 /712 external insulin pump systems
- Treatment with insulin pump at least 3 month prior to study entry
- An internet access from patient's home
- Age 0-35 years old
- HbA1c>7.8
- Signing inform consent forms
Exclusion Criteria:
- Any significant disease or conditions, including psychiatric disorders that in the opinion of the investigator are likely to effect his compliance or ability to complete the study
- Patients participating in other device or drug studies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 2
Regular treated group in the first segment and CareLink treated group in the second segment
|
At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month.
At the second segment of the study patients there will be home use of the CareLink System until the end of the study.
No further contact will be initiated by the study team.
|
Experimental: 1. CareLink team supported group
CareLink team supported group
|
At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team.
In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HbA1c
Time Frame: At Baseline and every 4 month after
|
At Baseline and every 4 month after
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hypoglycemic events
Time Frame: will be recorded through the whole study period
|
will be recorded through the whole study period
|
DKA and ketosis events
Time Frame: will be recorded through the whole study period
|
will be recorded through the whole study period
|
Patient's satisfaction and quality of life questionnaire
Time Frame: At baseline visit and every 4 months after
|
At baseline visit and every 4 months after
|
7 points glucose profile
Time Frame: Will be recorded 2 days before baseline visit and every 4 months after
|
Will be recorded 2 days before baseline visit and every 4 months after
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- rmc005047ctil
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on regular home use and Medtronic CareLink Therapy Management
-
Medtronic DiabetesCompletedType 1 DiabetesUnited States
-
Medtronic CardiovascularRecruitingAortic Stenosis Symptomatic | Moderate Aortic Valve StenosisUnited States, France, Netherlands, Canada, Spain, Israel, Australia, Denmark, Germany, Italy, Japan, Switzerland, Belgium, Sweden, Austria, United Kingdom, Ireland
-
University of MichiganDMG Dental Material Gesellschaft mbHCompleted
-
Bournemouth UniversityAECC University CollegeCompletedLow Back Pain, MechanicalUnited Kingdom
-
The First Affiliated Hospital of Xiamen UniversityFirst Affiliated Hospital of Fujian Medical University; Fujian Medical University... and other collaboratorsRecruitingAxial SpondyloarthritisChina
-
US Department of Veterans AffairsCompletedSmoking Cessation | Nicotine Replacement Therapy | Mood Tolerance | Mood ManagementUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Completed
-
Iowa City Veterans Affairs Medical CenterUS Department of Veterans AffairsCompleted
-
University Hospital BirminghamUnknownGraft Versus Host Disease | Nonneoplastic ConditionUnited Kingdom
-
Mark Vander WegVA Office of Research and DevelopmentUnknownTobacco Use | Nicotine DependenceUnited States